Bailard Inc. Acquires Shares of 19,500 biote Corp. (NASDAQ:BTMD)

Bailard Inc. bought a new position in shares of biote Corp. (NASDAQ:BTMD) during the fourth quarter, HoldingsChannel reports. The fund bought 19,500 shares of the company’s stock, valued at approximately $96,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of BTMD. SW Investment Management LLC purchased a new position in shares of biote during the third quarter worth about $3,340,000. Acadian Asset Management LLC acquired a new position in shares of biote in the third quarter valued at approximately $712,000. Mesirow Financial Investment Management Inc. purchased a new stake in shares of biote during the third quarter worth approximately $247,000. WINTON GROUP Ltd acquired a new stake in shares of biote during the third quarter worth $158,000. Finally, Allspring Global Investments Holdings LLC purchased a new position in biote in the 3rd quarter valued at $126,000. 21.68% of the stock is owned by hedge funds and other institutional investors.

biote Price Performance

biote stock opened at $5.48 on Tuesday. biote Corp. has a fifty-two week low of $3.65 and a fifty-two week high of $8.22. The stock has a fifty day moving average of $5.82 and a two-hundred day moving average of $5.17.

biote (NASDAQ:BTMD) last posted its quarterly earnings data on Tuesday, March 12th. The company reported $0.14 EPS for the quarter, beating analysts’ consensus estimates of $0.08 by $0.06. biote had a negative return on equity of 45.10% and a net margin of 1.79%. The business had revenue of $45.70 million for the quarter, compared to analyst estimates of $45.50 million. Research analysts predict that biote Corp. will post 0.39 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have recently commented on BTMD. Jefferies Financial Group initiated coverage on shares of biote in a research note on Thursday, February 1st. They issued a “buy” rating and a $6.55 target price for the company. B. Riley initiated coverage on shares of biote in a research report on Tuesday, February 20th. They set a “buy” rating and a $9.00 target price on the stock. Roth Mkm reaffirmed a “buy” rating and issued a $9.00 price objective (up from $8.00) on shares of biote in a research note on Wednesday, March 13th. Finally, Truist Financial decreased their price objective on shares of biote from $10.00 to $9.00 and set a “buy” rating on the stock in a research report on Thursday, January 18th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, biote presently has a consensus rating of “Buy” and a consensus price target of $8.11.

About biote

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.